Literature DB >> 22300217

Autologous transplantation of bone marrow-derived mesenchymal stem cells: a promising therapeutic strategy for prevention of skin-graft contraction.

Y Xu1, S Huang, X Fu.   

Abstract

Hypertrophic scars result from abnormal healing of severe burns, and are characterized by loss of the original structure and function of the skin. Transplantation of autologous split skin is the preferred treatment after scar excision; however, there will be some unavoidable degree of contraction within the grafts. To our knowledge, it is very rare that bone marrow-derived mesenchymal stem cells (BM-MSCs) have been used for the treatment of skin-graft contraction. However, in our clinics, we found that during a 2-year follow-up analysis, areas treated with autologous BM-MSCs combined with transplantation of split skin were less likely to have contraction of the skin grafts than areas treated with skin grafts alone. This result indicates that BM-MSCs may be a potential and promising treatment to prevent contraction of skin grafts. © The Author(s). CED
© 2012 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2012        PMID: 22300217     DOI: 10.1111/j.1365-2230.2011.04260.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  13 in total

Review 1.  Insights into bone marrow-derived mesenchymal stem cells safety for cutaneous repair and regeneration.

Authors:  Y Wu; S Huang; J Enhe; X Fu
Journal:  Int Wound J       Date:  2012-08-30       Impact factor: 3.315

2.  Secreted HoxA3 Promotes Epidermal Proliferation and Angiogenesis in Genetically Modified Three-Dimensional Composite Skin Constructs.

Authors:  Jennifer H Kuo; Ileana Cuevas; Amy Chen; Ashley Dunn; Mauricio Kuri; Nancy Boudreau
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-10-01       Impact factor: 4.730

Review 3.  New advances in the mesenchymal stem cells therapy against skin flaps necrosis.

Authors:  Fu-Gui Zhang; Xiu-Fa Tang
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

Review 4.  Stem cell-based therapy for human diseases.

Authors:  Duc M Hoang; Phuong T Pham; Trung Q Bach; Anh T L Ngo; Quyen T Nguyen; Trang T K Phan; Giang H Nguyen; Phuong T T Le; Van T Hoang; Nicholas R Forsyth; Michael Heke; Liem Thanh Nguyen
Journal:  Signal Transduct Target Ther       Date:  2022-08-06

Review 5.  Cell therapy in dermatology.

Authors:  Gabriela Petrof; Alya Abdul-Wahab; John A McGrath
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

6.  Targeting ectodysplasin promotor by CRISPR/dCas9-effector effectively induces the reprogramming of human bone marrow-derived mesenchymal stem cells into sweat gland-like cells.

Authors:  Sujing Sun; Jun Xiao; Jiahui Huo; Zhijun Geng; Kui Ma; Xiaoyan Sun; Xiaobing Fu
Journal:  Stem Cell Res Ther       Date:  2018-01-12       Impact factor: 6.832

Review 7.  3D bioprinting for skin tissue engineering: Current status and perspectives.

Authors:  Tingting Weng; Wei Zhang; Yilan Xia; Pan Wu; Min Yang; Ronghua Jin; Sizhan Xia; Jialiang Wang; Chuangang You; Chunmao Han; Xingang Wang
Journal:  J Tissue Eng       Date:  2021-07-13       Impact factor: 7.813

Review 8.  Cellular human tissue-engineered skin substitutes investigated for deep and difficult to heal injuries.

Authors:  Álvaro Sierra-Sánchez; Kevin H Kim; Gonzalo Blasco-Morente; Salvador Arias-Santiago
Journal:  NPJ Regen Med       Date:  2021-06-17

Review 9.  The Use of Stem Cells in Burn Wound Healing: A Review.

Authors:  Fadi Ghieh; Rosalyn Jurjus; Amir Ibrahim; Alice Gerges Geagea; Hisham Daouk; Bassel El Baba; Sana Chams; Michel Matar; Wadih Zein; Abdo Jurjus
Journal:  Biomed Res Int       Date:  2015-07-07       Impact factor: 3.411

10.  Role of Keratinocyte Growth Factor in the Differentiation of Sweat Gland-Like Cells From Human Umbilical Cord-Derived Mesenchymal Stem Cells.

Authors:  Yongan Xu; Yucai Hong; Mengyan Xu; Kui Ma; Xiaobing Fu; Mao Zhang; Guirong Wang
Journal:  Stem Cells Transl Med       Date:  2015-11-16       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.